uniQure NV (QURE) (Q3 2026) Earnings Call Highlights: FDA Priority Review for AMT-130 and a ...
uniQure NV (QURE) posted higher Q3 2026 revenue and $768.4 million in cash while advancing AMT-130 toward a May 2027 PDUFA date amid advisory committee uncertainty. Related Stocks: QURE ,